Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 128.40B |
| Revenue (ttm) | 11.02B |
| Net Income (ttm) | -535.60M |
| Shares Out | 256.79M |
| EPS (ttm) | -2.08 |
| PE Ratio | n/a |
| Forward PE | 27.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 588,832 |
| Open | 499.00 |
| Previous Close | 495.83 |
| Day's Range | 494.74 - 501.38 |
| 52-Week Range | 377.85 - 519.88 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 511.27 (+2.25%) |
| Earnings Date | May 5, 2025 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $511.27, which is an increase of 2.25% from the latest price.
News
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner Internati...
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike
The Investment Committee give you their top stocks to watch in this volatile markets.
GreensKeeper Q1 2025 Portfolio Update
Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fuele...
Vertex to Announce First Quarter 2025 Financial Results on May 5th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company w...
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elex...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollm...
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Evercore's "All-Weather" stock list: NRG Energy, Vistra, Vertex, IBM and ASML
The Investment Committee debate Evercore's "All-Weather" stock list and how you should trade these names.
Final Trades: Netflix, Meta, Vertex, Interactive Brokers and the COWZ
The Investment Committee give you their top stocks to watch for the second half.
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scie...
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET Company Participants David Altshuler - Executive Vice President, Glob...
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opini...
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.
Vertex to Participate in Upcoming March Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President a...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla...